The Chicago Entrepreneur

: FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments

The approval comes one day after the departure of Billy Dunn, the FDA’s head of neuroscience.

Previous post : Marqeta shares dive as first-quarter forecast comes up shy of expectations
Next post Crypto: Visa says crypto strategy unchanged after a report that it’s pausing new partnership efforts